Amgen Reports Phase 3 FREEDOM Results for Prolia in Postmenopausal Osteoporosis

Amgen today announced results from the Phase 3 FREEDOM trial evaluating Prolia (denosumab) in postmenopausal women with osteoporosis. The trial met its primary endpoint, demonstrating a significant reduction in new vertebral fractures with Prolia compared to placebo. Prolia also significantly reduced hip and nonvertebral fractures.